ArticleHerz2019
Effect of novel oral anticoagulants on Hospital Anxiety and Depression Scale scores.
Article in Herz, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Relationship between anxiety and depressive symptoms and social support in patients with atrial fibrillation.Revista brasileira de enfermagem · 2026Article
- Risk of suicide in patients with atrial fibrillation receiving different oral anticoagulants: a nationwide analysis using target trial emulation framework.BMC medicine · 2024Article
- Global epidemiology of mental disorder in atrial fibrillation between 1998-2021: A systematic review and meta-analysis.World journal of psychiatry · 2024Article
- Control of Therapeutic Levels of Anticoagulation and Associated Factors: A Prospective Cohort Study.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe negative impact of atrial fibrillation (AF) on health-related quality of life has been extensively documented. The aim of this study was to compare the Hospital Anxiety and Depression Scale (HADS) scores of patients with non-valvular AF during warfarin administration and after switching to novel oral anticoagulants (NOACs).
methodsThe study comprised 100 consecutive patients on warfarin treatment between July 2018 and January 2019 for whom a transition to NOACs was planned. All patients completed the HADS at the start of the study and at least 3 months after that date.
resultsThe mean value of HADS-A (5.9 ± 2.1 vs. 4.4 ± 1.6, p < 0.001) and HADS-D (4.4 ± 1.7 vs. 3.7 ± 1.4, p < 0.001) scores was significantly higher in patients when they used warfarin than when they switched to NOACs. Analysis revealed that there was a significant correlation between HADS-A and HADS-D scores with age and history of bleeding (p < 0.001). The highest scores were found for patients with a history of bleeding and age ≥75 years (p < 0.001).
conclusionOur study demonstrates that patients with nonvalvular AF under treatment with NOACs had lower HADS-A and HADS-D scores compared with patients on warfarin treatment. These findings suggest that NOACs may increase the quality of life and decrease morbidity and mortality by reducing anxiety and depression.
Indexed as
Identifiers
31236605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.